Full results of the ANNEXA-I trial, showing better control of hematoma expansion but an increase in thrombotic events with ...

LEXINGTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VYGR), a biotechnology company dedicated to advancing ...

Marking IgA Nephropathy Awareness Day, delve into the latest clinical trials that could redefine IgA nephropathy treatment ...

Company announcement - No. 26 / 2024Zealand Pharma Announces Financial Results for the First Quarter of 2024Strong performance in the first ...

A long list of potentials has been whittled down to make this year's list of Continental Europe's 25 future female leaders in ...

Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based ...

Good afternoon, and welcome to Voyager Therapeutics First Quarter 2024 Financial Results Conference Call. [Operator ...

Company announces clearance of IND application with FDA for anti-tau antibody VY-TAU01 for the treatment of Alzheimer’s disease; expect to ...

The new research shows that individuals who carry the V142I transthyretin variant are at significantly increased risk for heart failure beginning in their 60s, with an increased risk for death ...

Company announces clearance of IND application with FDA for anti-tau antibody VY-TAU01 for the treatment of Alzheimer's disease; expect to begin single ascending dose trial in the coming weeks - - ...

He also served on the boards of Wilson Therapeutics (Nasdaq Stockholm: WTX), acquired by Alexion, Therachon, acquired by Pfizer, and VectivBio (Nasdaq: VECT), acquired by Ironwood. "It has been a ...

Disability progression independent of relapse activity (PIRA) -- sometimes referred to as silent progression -- is a key ...